TradingKey

關於 Vanda Pharmaceuticals Inc 公司

Vanda Pharmaceuticals Inc. 是一家生物製藥公司，專注於開發和商業化療法，以滿足大量未滿足的醫療需求並改善患者的生活。該公司的商業產品組合由三種產品組成：HETLIOZ，用於治療非 24 小時睡眠-覺醒障礙 (Non-24) 和用於治療史密斯-馬吉尼斯綜合徵 (SMS) 的夜間睡眠障礙；Fanapt (伊潘立酮)，用於治療 I 型雙相情感障礙和用於治療精神分裂症的長效注射劑 (LAI)；PONVORY (ponesimod)，用於治療炎症/自身免疫性疾病，包括潰瘍性結腸炎、牛皮癬、克羅恩病、特應性皮炎、嗜酸性食管炎和斑禿。該公司還正在開發一系列藥物，包括 Tradipitant (VLY-686)、VHX-896、VSJ-110、VPO-227、VTR-297、VQW-765、VCA-894A 和 Type 2S (CMT2S)。

公司簡介

公司代碼VNDA

公司名稱Vanda Pharmaceuticals Inc

上市日期Apr 12, 2006

CEODr. Mihael Hristos Polymeropoulos, M.D.

員工數量368

證券類型Ordinary Share

年結日Apr 12

公司地址Suite 300E

城市WASHINGTON

上市交易所NASDAQ Global Market Consolidated

國家United States of America

郵編20037

電話12027343400

網址https://www.vandapharma.com/

公司代碼VNDA

上市日期Apr 12, 2006

CEODr. Mihael Hristos Polymeropoulos, M.D.

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.33M

+1.31%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

Dr. Stephen Ray Mitchell, M.D.

Independent Director

97.08K

+116.43%

Mr. Timothy I. Williams

Senior Vice President, General Counsel, Secretary

--

Ms. Phaedra S. Chrousos

Independent Director

--

Mr. Joakim (Kim) Wijkstrom

Senior Vice President, Chief Marketing Officer

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.33M

+1.31%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Fanapt

23.55M

47.05%

Hetlioz

20.87M

41.71%

PONVORY

5.62M

11.24%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

Fanapt

23.55M

47.05%

Hetlioz

20.87M

41.71%

PONVORY

5.62M

11.24%

股東統計

更新時間: 5月16日週五

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

10.18%

Renaissance Technologies LLC

6.04%

The Vanguard Group, Inc.

5.92%

Millennium Management LLC

5.28%

Dimensional Fund Advisors, L.P.

4.30%

Other

68.29%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

10.18%

Renaissance Technologies LLC

6.04%

The Vanguard Group, Inc.

5.92%

Millennium Management LLC

5.28%

Dimensional Fund Advisors, L.P.

4.30%

Other

68.29%

股東類型

持股股東

佔比

Investment Advisor

28.86%

Investment Advisor/Hedge Fund

26.88%

Hedge Fund

19.28%

Individual Investor

7.20%

Research Firm

2.93%

Pension Fund

0.44%

Bank and Trust

0.20%

Sovereign Wealth Fund

0.20%

Venture Capital

0.12%

Other

13.90%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

415

50.78M

86.17%

-11.31M

2025Q1

426

48.51M

82.37%

-12.27M

2024Q4

444

46.48M

79.71%

-15.23M

2024Q3

446

47.42M

81.36%

-14.93M

2024Q2

445

46.99M

80.73%

-18.42M

2024Q1

434

53.50M

92.97%

-11.41M

2023Q4

445

55.38M

96.27%

-9.21M

2023Q3

446

56.79M

98.75%

-12.15M

2023Q2

434

60.42M

105.19%

-10.16M

2023Q1

437

62.04M

109.27%

-2.85M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

6.02M

10.21%

+16.86K

+0.28%

Mar 31, 2025

Renaissance Technologies LLC

3.57M

6.05%

-287.37K

-7.46%

Mar 31, 2025

The Vanguard Group, Inc.

3.50M

5.93%

-11.00K

-0.31%

Mar 31, 2025

Millennium Management LLC

3.12M

5.29%

+980.75K

+45.84%

Jun 27, 2025

Dimensional Fund Advisors, L.P.

2.54M

4.31%

+51.16K

+2.06%

Mar 31, 2025

Tang Capital Management, LLC

2.35M

3.99%

--

Mar 31, 2025

Polymeropoulos (Mihael Hristos)

2.33M

3.95%

+30.00K

+1.31%

May 21, 2025

BlackRock Financial Management, Inc.

2.15M

3.64%

+14.97K

+0.70%

Mar 31, 2025

Acadian Asset Management LLC

1.89M

3.2%

-12.95K

-0.68%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.61M

2.74%

+163.33K

+11.26%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

iShares Neuroscience and Healthcare ETF

0.64%

Invesco NASDAQ Future Gen 200 ETF

0.49%

ALPS Medical Breakthroughs ETF

0.19%

SPDR SSGA US Small Cap Low Volatility Index ETF

0.13%

Fidelity Small-Mid Multifactor ETF

0.09%

Federated Hermes MDT Small Cap Core ETF

0.08%

iShares Micro-Cap ETF

0.06%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.04%

Franklin US Small Cap Multifactor Index ETF

0.04%

Fidelity Enhanced Small Cap ETF

0.03%

iShares Neuroscience and Healthcare ETF

佔比0.64%

Invesco NASDAQ Future Gen 200 ETF

佔比0.49%

ALPS Medical Breakthroughs ETF

佔比0.19%

SPDR SSGA US Small Cap Low Volatility Index ETF

佔比0.13%

Fidelity Small-Mid Multifactor ETF

佔比0.09%

Federated Hermes MDT Small Cap Core ETF

佔比0.08%

iShares Micro-Cap ETF

佔比0.06%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0.04%

Franklin US Small Cap Multifactor Index ETF

佔比0.04%

Fidelity Enhanced Small Cap ETF

佔比0.03%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Vanda Pharmaceuticals Inc

4.205USD

Vanda Pharmaceuticals Inc

4.205

概覽

公司

財務